Allos Therapeutics, Inc.

210 articles about Allos Therapeutics, Inc.

• Allos Therapeutics, Inc. Announces Interim Results from Phase 1 Combination Study of FOLOTYN® and Bexarotene Demonstrate Activity in Patients with Relapsed or Refractory Cutaneous T-cell Lymphoma

  1/30/2012

• Allos Therapeutics, Inc. Receives Negative Opinion from the CHMP on FOLOTYN

  1/20/2012

• Allos Therapeutics, Inc. Reports 2011 Financial Highlights and Key Business Priorities

  1/10/2012

• Allos Therapeutics, Inc. Invites Investors to Listen to Webcast of Presentation at J.P. Morgan Healthcare Conference

  12/21/2011

• Allos Therapeutics, Inc. Reports Third Quarter 2011 Financial Results

  11/3/2011

• Allos Therapeutics, Inc., AMAG Pharmaceuticals, Inc. Merger Called Off

  10/21/2011

• Allos Therapeutics, Inc. Announces Settlement with Putative Class Action Plaintiffs Regarding Merger with AMAG Pharmaceuticals, Inc.

  10/14/2011

• Allos Therapeutics, Inc. Continues to Work Toward Completion of Merger with AMAG Pharmaceuticals, Inc.

  10/10/2011

• Allos Therapeutics, Inc. Initiates Phase 3 Registration Trial of FOLOTYN(R) in Newly Diagnosed Patients with Peripheral T-Cell Lymphoma Following Treatment with a CHOP-based Regimen

  8/17/2011

• Allos Therapeutics, Inc. Reports Second Quarter 2011 Financial Results

  8/5/2011

• AMAG Pharmaceuticals, Inc. Investor MSMB Makes $378 Million Takeover Bid for Firm to Stop Merger With Allos Therapeutics, Inc.

  8/3/2011

• Allos Therapeutics, Inc. to Report Second Quarter 2011 Results on August 4, 2011

  7/28/2011

• AMAG Pharmaceuticals, Inc., Allos Therapeutics, Inc. to Merge in $686 Million Deal

  7/20/2011

• Allos Therapeutics, Inc. Release: Data Shows Activity of FOLOTYN(R) in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma Following Treatment with CHOP

  6/20/2011

• Allos Therapeutics, Inc. Release: Data Suggests Treatment with FOLOTYN(R) Reverses Trend of Progressive Resistance Observed in Patients with Drug-Resistant Relapsed or Refractory Peripheral T-Cell Lymphoma

  6/17/2011

• ClinTec GmbH: COMPLETE Registry Provides First Glance into Treatment Patterns for Patients with Peripheral T-Cell Lymphoma

  6/16/2011

• Allos Therapeutics, Inc.'s FOLOTYN(R) Data to be Presented at the Congress of the European Hematology Association and the International Conference on Malignant Lymphoma

  6/8/2011

• Allos Therapeutics, Inc. and Mundipharma AG Announce Strategic Collaboration for FOLOTYN; Allos to Receive $50 Million Upfront; Potentially up to $310.5 Million

  5/11/2011

• Allos Therapeutics, Inc. to Present at Upcoming Investor Conferences in May

  5/4/2011

• Allos Therapeutics, Inc. to Report First Quarter 2011 Results on May 10, 2011

  5/3/2011